|
|
- 2019
Alzheimer's disease drug development pipeline: 2019DOI: 10.1016/j.trci.2019.05.008 Keywords: Alzheimer's disease, Drug development, Clinical trials, Biomarkers, Bayesian design, Adaptive design, Repurposed drugs Abstract: Alzheimer's disease (AD) has few available treatments, and there is a high rate of failure in AD drug development programs. Study of the AD drug development pipeline can provide insight into the evolution of drug development and how best to optimize development practices
|
